DK263390A - Flagellinrekombinantgener, undeinsyrekloner, mikroorganismer, proteiner og vacciner indeholdende dem samt fremgangsmaade til deres ekspression - Google Patents

Flagellinrekombinantgener, undeinsyrekloner, mikroorganismer, proteiner og vacciner indeholdende dem samt fremgangsmaade til deres ekspression Download PDF

Info

Publication number
DK263390A
DK263390A DK263390A DK263390A DK263390A DK 263390 A DK263390 A DK 263390A DK 263390 A DK263390 A DK 263390A DK 263390 A DK263390 A DK 263390A DK 263390 A DK263390 A DK 263390A
Authority
DK
Denmark
Prior art keywords
proteins
flagellin
recombinant
epitope
genes
Prior art date
Application number
DK263390A
Other languages
English (en)
Other versions
DK263390D0 (da
Inventor
William Robert Marjarian
Bruce Arnold Dunbar Stocker
Salete Maria Cardozo Newton
Original Assignee
Praxis Biolog Inc
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Biolog Inc, Univ Leland Stanford Junior filed Critical Praxis Biolog Inc
Publication of DK263390D0 publication Critical patent/DK263390D0/da
Publication of DK263390A publication Critical patent/DK263390A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK263390A 1988-05-05 1990-11-02 Flagellinrekombinantgener, undeinsyrekloner, mikroorganismer, proteiner og vacciner indeholdende dem samt fremgangsmaade til deres ekspression DK263390A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19057088A 1988-05-05 1988-05-05
PCT/US1989/001932 WO1989010967A1 (en) 1988-05-05 1989-05-05 Recombinant flagellin vaccines

Publications (2)

Publication Number Publication Date
DK263390D0 DK263390D0 (da) 1990-11-02
DK263390A true DK263390A (da) 1991-01-04

Family

ID=22701885

Family Applications (1)

Application Number Title Priority Date Filing Date
DK263390A DK263390A (da) 1988-05-05 1990-11-02 Flagellinrekombinantgener, undeinsyrekloner, mikroorganismer, proteiner og vacciner indeholdende dem samt fremgangsmaade til deres ekspression

Country Status (10)

Country Link
EP (1) EP0419513B1 (da)
JP (1) JP2793673B2 (da)
AT (1) ATE121782T1 (da)
AU (1) AU637049B2 (da)
CA (1) CA1340817C (da)
DE (1) DE68922394T2 (da)
DK (1) DK263390A (da)
FI (1) FI104638B (da)
NO (1) NO302031B1 (da)
WO (1) WO1989010967A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698390A (en) * 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
US5712088A (en) * 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US6861212B1 (en) 1987-11-18 2005-03-01 Chiron Corporation NANBV diagnostics and vaccines
US6171782B1 (en) 1987-11-18 2001-01-09 Chiron Corporation Antibody compositions to HCV and uses thereof
US5714596A (en) * 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
EP0449958B9 (en) * 1988-12-19 2003-05-28 American Cyanamid Company Meningococcal class 1 outer-membrane protein vaccine
US6027729A (en) * 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
ATE190656T1 (de) * 1990-10-01 2000-04-15 Mini Agriculture & Fisheries Verfahren zur prüfung für salmonella
ATE155169T1 (de) * 1990-10-01 1997-07-15 Mini Agriculture & Fisheries Polynukleotidsequenz von salmonella
GB9101550D0 (en) * 1991-01-24 1991-03-06 Mastico Robert A Antigen-presenting chimaeric protein
IL101639A0 (en) * 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
TR200401569T4 (tr) * 1999-12-28 2004-07-21 Akzo Nobel N.V. Flagelin ya da flagelle'ya karşı antikorların oluşumuna sebep olmayan salmonelle aşısı
WO2004055045A1 (ja) * 2002-12-16 2004-07-01 Caf Laboratories Inc. サルモネラ抗原処方物、それを使用した抗体検査キット及びサブユニットワクチン
US20080248068A1 (en) 2004-05-07 2008-10-09 Hans-Gustaf Ljunggren Use of Flagellin as an Adjuvant for Vaccine
EP1836221B1 (en) 2004-12-02 2011-08-03 Csir Gram positive bacterial cells comprising a disrupted flagellin gene, flagellin-based fusion proteins and use in removal of metal ions from a liquid
EP1827489B1 (en) 2004-12-16 2012-10-31 Wake Forest University Health Sciences Use of flagellin in tumor immunotherapy
US8420102B2 (en) 2006-03-07 2013-04-16 Vaxinnate Corporation Compositions that include hemagglutinin
EP2374474A1 (en) 2005-01-19 2011-10-12 Vaxinnate Corporation Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
AU2009236585B2 (en) 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
CN102816246B (zh) * 2012-09-04 2014-07-23 成都蓉生药业有限责任公司 一种人巨细胞病毒免疫原融合蛋白及其制备方法和用途
JP2017530114A (ja) 2014-09-26 2017-10-12 バヴァリアン・ノルディック・アクティーゼルスカブ フラジェリンをコードする組み換えｍｖａによる鼻腔内免疫のための方法と組成物
EP3221464B1 (en) * 2014-11-18 2022-02-23 The Trustees of Columbia University in the City of New York Detection of analytes using live cells
CN104402974B (zh) * 2014-12-10 2017-11-14 重庆医科大学 一种具有粘膜免疫佐剂活性的多肽及其在制备粘膜免疫佐剂中的用途
US10849938B2 (en) 2017-09-13 2020-12-01 ZBiotics Company Gene expression system for probiotic microorganisms
US10806778B2 (en) * 2019-01-30 2020-10-20 Prokarium Limited Modified strain of Salmonella enterica Typhi

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735801A (en) * 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
WO1987002385A1 (en) * 1985-10-11 1987-04-23 Genetics Institute, Inc. Method for producing heterologous proteins
EP0237045B1 (en) * 1986-03-11 1993-10-20 Shionogi & Co., Ltd. DNA encoding flagellin and vector having the same
CA1331355C (en) * 1986-04-21 1994-08-09 Bioenterprises Pty. Ltd Immunopotentation

Also Published As

Publication number Publication date
EP0419513B1 (en) 1995-04-26
NO904806L (no) 1991-01-03
DE68922394T2 (de) 1995-10-05
NO904806D0 (no) 1990-11-05
AU3697989A (en) 1989-11-29
FI905441A0 (fi) 1990-11-02
AU637049B2 (en) 1993-05-20
WO1989010967A1 (en) 1989-11-16
EP0419513A1 (en) 1991-04-03
ATE121782T1 (de) 1995-05-15
JPH04502402A (ja) 1992-05-07
JP2793673B2 (ja) 1998-09-03
DE68922394D1 (de) 1995-06-01
FI104638B (fi) 2000-03-15
CA1340817C (en) 1999-11-09
DK263390D0 (da) 1990-11-02
NO302031B1 (no) 1998-01-12

Similar Documents

Publication Publication Date Title
DK263390A (da) Flagellinrekombinantgener, undeinsyrekloner, mikroorganismer, proteiner og vacciner indeholdende dem samt fremgangsmaade til deres ekspression
Ulmer Influenza DNA vaccines
EP2949340A1 (en) Vaccine composition against Streptococcus suis infection
DK2311848T3 (da) Kodon-optimerede polynukleotidbaserede vacciner mod human cytomegalovirus-infektion
DK153290A (da) Polypeptid, vaccine indeholdende dette og ekspressionssystem indeholdende en dna-sekvens, der kan udtrykke polypeptidet
EP0658120A4 (en) CONJUGATES OF WEAK IMMUNOGENIC ANTIOGENIC AND SYNTHETIC PEPTIDE CARRIERS AND VACCINE SUBSTANCES THEREOF.
WO2005046621A3 (en) Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines
Liu et al. DNA vaccines: mechanisms for generation of immune responses
Bäckström et al. Insertion of a HIV-1-neutralizing epitope in a surface-exposed internal region of the cholera toxin B-subunit
Rollier et al. Early life humoral response of ducks to DNA immunization against hepadnavirus large envelope protein
JP2021505529A (ja) ネコカリシウイルスワクチン
Muller et al. Immunogenic measles antigens expressed in plants: role as an edible vaccine for adults
Rath et al. DNA vaccine for rabies: relevance of the trans-membrane domain of the glycoprotein in generating an antibody response
KR920006503A (ko) 살모넬라 백신 균주의 표면에 면역원성 말라리아 항원을 발현할수 있는 재조합 발현 벡터
Perrin et al. DNA-based immunization against Lyssaviruses
Arnon et al. Peptide-based synthetic recombinant vaccines with anti-viral efficacy
Tafuku et al. Japanese encephalitis virus structural and nonstructural proteins expressed in Escherichia coli induce protective immunity in mice
JIANG et al. Effects of the configuration of a multi-epitope chimeric malaria DNA vaccine on its antigenicity to mice
Grosfeld et al. Delineation of protective epitopes on the E2-envelope glycoprotein of Semliki Forest virus
Kondo et al. A protective effect of epidermal powder immunization in a mouse model of equine herpesvirus-1 infection
WO2025191546A2 (en) Chimeric virus-like particle vaccine against rotavirus
GB8431253D0 (en) Biological preparations
Ada Desirable immunologic characteristics for the development of an ideal vaccine
Smith et al. Potential for GTF-based synthetic peptides in a dental caries vaccine
Jenkins et al. Enhanced delivery systems for enteric antigen uptake in teleosts

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment